

Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs

Information for the public

Published: 2 February 2022

www.nice.org.uk

Upadacitinib (Rinvoq), taken with or without methotrexate, is available on the NHS. It is a possible treatment for active psoriatic arthritis when disease modifying antirheumatic drugs (DMARDs) have not worked well enough or are not tolerated. It is only for adults who have peripheral arthritis with 3 or more tender joints and 3 or more swollen joints and:

- they have had 2 conventional DMARDs or at least 1 biological DMARD or
- TNF-alpha inhibitors would be used but the person cannot have them.

Only people whose psoriatic arthritis improves enough by 12 weeks can carry on with treatment.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Psoriasis and Psoriatic Arthritis Alliance](#) (PAPAA), 0192 367 2837
- [Psoriasis Association](#), 0160 425 1620

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4424-8